The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder
Abstract
OBJECTIVE: This study was designed to determine the minimum paroxetine dose effective for treating panic disorder. METHOD: Of 425 patients with DSM-III-R panic disorder with or without agoraphobia who underwent a 2-week drug-free screening period, 278 patients were randomly assigned to double-blind treatment with a 10-week course of placebo or paroxetine at a dose of 10, 20, or 40 mg/day. RESULTS: At 40 mg/day, paroxetine was superior to placebo across the majority of outcome measures. Despite a mean of 9.5 to 11.6 full panic attacks during the screening period, 86.0% of the patients taking 40 mg of paroxetine, 65.2% of those taking 20 mg, 67.4% of those taking 10 mg, and 50.0% of the placebo-treated patients were free of full panic attacks during the 2 weeks ending at week 10. The 40-mg paroxetine group experienced significantly greater global improvement than the placebo group and significantly greater improvement in frequency of full and limited-symptom panic attacks, intensity of full panic attacks, phobic fear, anxiety, and depressive symptoms, usually evident by week 4. All doses of paroxetine were well tolerated, and adverse effects were consistent with those associated with selective serotonin reuptake inhibitors. CONCLUSIONS: Paroxetine is an effective and well-tolerated short-term treatment of panic disorder. The minimum dose demonstrated to be significantly superior to placebo was 40 mg/day, although some patients did respond at lower doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Brief standard self-rating for phobic patients
Marks, I. M., & Mathews, A. M. (1979) · Behaviour Research and Therapy · doi:10.1016/0005-7967(79)90041-x · Cited by 1,801
Ballenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale
Leon, A. C., Shear, M. K., Portera, L., & Klerman, G. L. (1992) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00788510 · Cited by 319
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…of randomised fixeddose placebo-controlled studies suggest that higher daily doses of some antidepressants [I (PCT)] (paroxetine, fluoxetine: Ballenger et al., 1998; Michelson et al., 1998) but not others [I (PCT)] (citalopram, venlafaxine: Pollack et al., 2007; Wade et al., 1997) may be…”
BackgroundEffects of SSRIs on Sexual Function: A Critical Review
Rosen, R. C., Lane, R. M., & Menza, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00013 · Cited by 650
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Sheehan, K. H., & Sheehan, D. V. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b4d6 · Cited by 467
Efficacy and Safety of Paroxetine Treatment for Chronic PTSD: A Fixed-Dose, Placebo-Controlled Study
Marshall, R. D., Beebe, K. L., Oldham, M., & Zaninelli, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.1982 · Cited by 432
Bourin, M., Chue, P., & Guillon, Y. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00189.x · Cited by 408
Mitte, K. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.05.003 · Cited by 396
L??o, H., Hale, A., & D??haenen, H. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00004 · Cited by 361
Gaps in accessing treatment for anxiety and depression: challenges for the delivery of care
Collins, K. A., Westra, H. A., Dozois, D. J. A., & Burns, D. D. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.06.001 · Cited by 322
Paroxetine: An Update of Its Use in Psychiatric Disorders in Adults
Wagstaff, A. J., Cheer, S. M., Matheson, A. J., Ormrod, D., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262040-00010 · Cited by 287
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction
Montgomery, S. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00313-5 · Cited by 205
Rief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J. (2009) · Drug Safety · doi:10.2165/11316580-000000000-00000 · Cited by 202
Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
Kent, J. M., Coplan, J. D., & Gorman, J. M. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00210-8 · Cited by 196
Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology
Goodnick, P. J., & Goldstein, B. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003021 · Cited by 183
Goldstein, B. J., & Goodnick, P. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003041 · Cited by 171
Roy-Byrne, P. P., Katon, W., Cowley, D. S., & Russo, J. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.869 · Cited by 158
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101
CBT Intensity and Outcome for Panic Disorder in a Primary Care Setting
Craske, M. G., Roy-Byrne, P., Stein, M. B., Sullivan, G., Hazlett-Stevens, H., Bystritsky, A., & Sherbourne, C. (2006) · Behavior Therapy · doi:10.1016/j.beth.2005.05.003 · Cited by 94
Anxiety and Depression: Optimizing Treatments
Ballenger, J. C. (2000) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v02n0301 · Cited by 83
Self-citationMinority inclusion in randomized clinical trials of panic disorder
Mendoza, D. B., Williams, M. T., Chapman, L. K., & Powers, M. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.02.011 · Cited by 70
Risks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1429403 · Cited by 62
Michelson, D., Allgulander, C., Dantendorfer, K., Knezevic, A., Maierhofer, D., Micev, V., Paunovic, V. R., Timotijevic, I., Sarkar, N., Skoglund, L., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.514 · Cited by 62
Treatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57
Sugarman, M. A., Loree, A. M., Baltes, B. B., Grekin, E. R., & Kirsch, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106337 · Cited by 55
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Simon, N. M., Otto, M. W., Worthington, J. J., Hoge, E. A., Thompson, E. H., LeBeau, R. T., Moshier, S. J., Zalta, A. K., & Pollack, M. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04485blu · Cited by 45
Jeejeebhoy, F. M., Dorian, P., & Newman, D. M. (2000) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(99)00103-8 · Cited by 46
Panic Disorder and Chest Pain: Mechanisms, Morbidity, and Management
Huffman, J. C., Pollack, M. H., & Stern, T. A. (2002) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v04n0203 · Cited by 35
Pharmacotherapy of panic disorder
Pull, C. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1224 · Cited by 32
Safer, D. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000564 · Cited by 19
Choi, K.-W., Woo, J.-M., Kim, Y.-R., Lee, S.-H., Lee, S.-Y., Kim, E.-J., Chung, S.-K., Kang, E.-H., Lee, J.-H., & Yu, B.-H. (2012) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2012.10.1.44 · Cited by 17
Metadata
- Authors
- Ballenger, J. C., Wheadon, D. E., Steiner, M., Bushnell, W., & Gergel, I. P.
- Venue
- American Journal of Psychiatry
- Published
- 1998-01-01
- Volume
- 155
- Issue
- 1
- Pages
- 36-42
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2094918976
- Cited by
- 220
- References
- 6
- FWCI
- 33.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.